A Phase I Study Evaluating the Safety and Imaging Characteristics of 18F-LY3546117 Injection in Subjects Who Are Undergoing Treatment With Immune Checkpoint Inhibitors
Latest Information Update: 05 Apr 2024
At a glance
- Drugs 18F-LY3546117 (Primary)
- Indications Cancer; Malignant melanoma; Non-small cell lung cancer
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 22 Apr 2022 Planned End Date changed from 1 Mar 2024 to 1 Apr 2024.
- 22 Apr 2022 Planned primary completion date changed from 1 Mar 2024 to 1 Apr 2024.
- 04 Mar 2022 Planned End Date changed from 1 Oct 2022 to 1 Mar 2024.